A federal judge has thrown out several claims against the makers of Prevacid, a heartburn drug, but allowed several others, including one on a theory of manufacturing defect, that allege the product weakened a patient’s bones to the point of fracture, to survive.
Of the 14 claims filed earlier this year against Takeda Pharmaceuticals, which makes the drug, the company moved to dismiss 11 counts. Weighing issues on which courts in the district have split, U.S. District Judge Jan DuBois of the Eastern District of Pennsylvania came down largely on the side of the plaintiff, David S. Tatum.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
